Medición de translucencia nucal en fetos entre 11 y 14 semanas de gestación

Article Sidebar

PDF (Spanish)
Published: 2024-11-29
DOI: https://doi.org/10.56443/vt79pp26
Keywords:
Fetal alterations, Congenital anomalies, Diagnosis ultrasound, Nuchal translucency

Main Article Content

Rosario García Mandujano
José Luis Larios Reyes

Abstract

Genetic factors play an important roll in the de- velopment of human diseases. The screening for fetal alterations is the most powerful way to diminish the prevalence in newborns with congenital anomalies and increase the chances of survival for those born alive.

Article Details

Issue

Vol. 60 No. 1 (2006): Enero - Febrero

Section

Artículos de investigación

How to Cite

1.
Medición de translucencia nucal en fetos entre 11 y 14 semanas de gestación. RSM [Internet]. 2024 Nov. 29 [cited 2026 Jun. 21];60(1). Available from: https://www.revistasanidadmilitar.org/index.php/rsm/article/view/1912

References

1. Scriver CR. Human genes: determinants of sick populations and sick patients. Canadian journal of public health. Revue Canadienne de sante publique 1988; 79: 222-4.

2. World Health Association. Primary Health care approaches for prevention and control of congenital and genetic disorder. Report of a WHO meeting. Cairo, Egypt; 1999.

3. Baird PA, et al. Genetic disorders in children and young adults: a population study. Am J Hum Gen 1988; 42: 677-93.

4. Buyrse ML (ed). Birth defect encyclopedia. Dover, Center for Birth Defects Information Services Incorporated, Cambridge, Massachusetts, Blackwell Scientific Publications; 1990.

5. Simpson JL. Genetic counseling and prenatal diagnosis. In: Gabbe SG, Niebyl JR, Simpson JL. Obstetric normal and problem pregnancies. New York: Churchill Livingstone; 1996, p. 216.

6. Halliday JL, Watson LF, Lumley J, Danks DM, et al. New estimates of Down syndrome risks at chorionic villus sampling, amniocentesis and

liveborth in women of advanced maternal age from a uniquely defined population. Prenat Diagn 1995; 15(5): 455-65.

7. Callen PW. Ecografía en obstetricia y ginecología. 4ª Ed. Madrid, España: Ed. Panamericana; 2002.

8. Nicolaides KH, Sebire NJ, Snijders RJM, Ximenes RLS. The 11-14-weeks scan. In: Diploma in Fetal Medicine and ISUOG Educational Series.

9. Valenti C, Schultta EJ, Kehaty T. Prenatal diagnosis of Down's syndrome. Lancet 1968; 2: 220.

10. Copel JA, Bahado-Singh RO. Prenatal screening for Down's syndrome. A search for the family's values. N Engl K 1999; 341: 521.

11. Merkatz IR, Nitowski HM, Macri JN. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148: 886-92.

12. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha- fetoprotein measurements: a screening test for Down syndrome. Lancet 1984; 323: 926-33